Thursday, Oct 23 2014
All Cities
Choose Your City
'The Eastern Section of the Great Vasyugan Mire has been nominated for the Unesco World Heritage List'
A.J.Haywood

A major breakthrough in treating Parkinson's Disease cannot reach patients

By The Siberian Times reporter
29 August 2012

Pioneering and promising work by Siberian scientists in countering this debilitating motor system disorder is stalled due to a lack of funds for vital additional research, and no proper system for developing new drugs, it is claimed.

Specialists at the Vorozhtsov Institute of Organic Chemistry in Novosibirsk believe they have had a breakthrough in treating Parkinson's Disease (PD), but now find their hands tied.

'We have synthesized a compound which completely removes all symptoms of Parkinson's disease in animals,' leading researcher Konstantin Volcho told the press-service of the  Siberian Branch of Russian Academy of Science.

'Tests on animals with PD demonstrated that the medicine returns all parameters back to normal and does not require additional medication. It has also been proven by long-term experiments.'

The medicine will not cure PD completely, yet the Siberian specialists say it is a breakthrough in PD treatment as it allows patients to live a normal, healthy life for a longer period.

'Currently there is no cure for Parkinson's disease, the main target of PD treatment is to give patients the maximum quality of life for as long as possible.'

Yet since their breakthrough was first highlighted in 2010, the scientists have struggled to complete the additional tests that must be conducted before exposing their drugs to humans.

In other countries, big drugs companies have special departments to 'promote' the future of medicine, while in Russia this work has to be done by the researchers, said Volcho.

Having made the breakthrough with a new compound shown as highly effective on animals, there should be a back-up system 'to deal with its pre-clinical and clinical studies and commercialisation', he said. 'But we don't have such special people.'

Calling for a drugs development centre in Novosibirsk, he said: 'We would have been able to transfer research into development centre at the stage where it is proved that the animal tests went well, which means that you can move to the next stage.'

Such a centre would do synthesis and pre-clinical studies of new drugs, as well as the development of dosage forms.

'Large pharmaceutical companies are working with materials that are shown to be effective in the second stage of clinical trials. And we cannot bring the development to this phase by ourselves,' he said. 

The scientists are currently continuing the work as best they can, and seeking money for full pre-clinical trials which the institute cannot afford. 

The total cost of pre-clinical trials is put at around 40 million roubles - about  $1.25 million - and their successful completion is a prerequisite to start testing on humans.

The Novosibirsk team say their compound known as DIOL does not have the side effects for PD sufferers that the widely used drug Levodopa can cause. 

Without additional tests and then - at the appropriate moment - trials on PD sufferers, the drug cannot reach the market, however good it maybe. 


PD is a motor system disorder, which occurs due to the death of dopamine-producing brain cells. It is typically found in people over the age of 50, and is more common in women, than men. The four primary symptoms of PD are tremor, stiffness of the limbs and trunk, slowness of movement and impaired balance and coordination.

According to the U.S. National Institute of Neurological Disorders and Stroke, nearly one million Americans are living with the disease, and 60,000 were diagnosed last year.

The symptoms are initially very mild, but when they start progressing, doctors usually prescribe medicines to replace the brain's lost dopamine. The extremely severe patients have to undergo brain surgery.

Comments (7)

Ita totally immoral if this is affective as is being said that research funds are notbeing used to advance this treatment,once again it seems the drugs companies are being looked after when there drugs might not be sold.
alan robertson, kelso,uk
07/08/2013 03:17
0
0
Roger, generally, interest from big pharmas require a completion of phase II clinical trials, otherwise it is too risky to get involved.
Liz, Steve, FYI: The Lancet, Volume 372, Issue 9634, Pages 207 - 215, 19 July 2008
it was another promising drug from Russia, which had a big success in phase II clinical trials then failed in phase III after it was in licensed to Pfizer. It was tested in humans for Alzheimer's disease, but was prooved to be also good to treat other neurodegenerative disorders.
Sergey Sablin, Bay Area, CA
05/08/2013 22:26
0
0
surely there will be major pharmaceutical companies that will be interested in a partnership with the scientists or the particular institution/organization they are working in to explore the possibility of funding further research and development to bring this product to commercial status. Pharma companies spend billions of dollars in research involving compounds that never pan out to anything, here we have (at least it sounds like) a pretty good outlook of something that will pass the various stages and clinical tests.. have they tried contacting PHRMA or any of the multinational drug companies directly (such as Abbott, Astra Zeneca, Roche, Lilly, etc.?)??
roger lohman, usa
05/08/2013 20:29
0
0
Can somebody give me a way to get in touch with these scientist or anyway to contact them??? Any information in relation to them to see what we could do to help....please
Liz Munaylla, Palm Beach, FL USA
04/03/2013 09:34
0
0
Steve, from what i've read http://exabytetechservices.com/xml/678-all-20120605-m/23675161N.article.fulltext.000001.pdf this may be applicable to MSA. MSA is not always rapid, sometimes it is slow. I've heard of people living 20 years or more with MSA. This isn't a cure, but it might help with symptoms for many years while a cure is found. Keep hope alive.
paul wright, australia
22/09/2012 20:37
1
0
Will this also work people who have aTypical Parkinsonism , I have MSA (multiple System Atroohy) which is afrom of Parkinsons , but it developes alot quicker I am 46 and really hope that this could be rhe start of acure
Steve Booth, Cheshire
22/09/2012 02:21
0
0
i have posted a link to this story on the parkinson's uk forum. there is a lack off detail about what this treatment involves - can that be found anywhere?
paul wright, australia
21/09/2012 18:30
0
0
1

Add your comment

We welcome a healthy debate, but do not accept offensive or abusive comments. Please also read 'Siberian Times' Privacy Policy

Name

Town/Country

Add your comments

The views expressed in the comments above are those of our readers. 'Siberian Times' reserves the right to pre-moderate some comments.

Control code*

Type the code

* obligatory


News

Business

The Bank of Russia official exchange rates of foreign currencies
EUR52.4424USD41.4958GBP66.5427Other...